Management team

Ada Kruisbeek

Prof. Dr. Ada Kruisbeek, Founder, CEO & CSO

Ada Kruisbeek is responsible for the overall scientific agenda of DCPrime. She has more than 30 years of managerial experience in science and business, and is an expert in immunology whose career has been dedicated to immunity against cancer, first in academic settings, and later in industry. Ada Kruisbeek worked at the National Institutes of Health, Bethesda, MD, USA, from 1978 until 1992, at the forefront of research that revealed how the immune system develops. She then became Head of the Department of Immunology at the Nederlands Kanker Instituut-Antoni van Leeuwenhoekhuis (NKI-AVL) in Amsterdam from 1992 till 2001. She published over 140 papers, many of which appeared in peer-reviewed top-journals, and she served on multiple advisory boards of national and international scientific agencies, research institutes and companies. In 2001, she moved to industry and became Senior Vice-President Research at Crucell BV, responsible for building up the cancer antibody pipeline. In 2004, when Crucell closed its oncology programs, Ada moved to the Vrije Universiteit (VU) in Amsterdam and became Director of the Cancer Center Amsterdam, founded the Technology Transfer Office (TTO) in 2005, DCPrime in 2006, and the Life Sciences Center Amsterdam in 2007.

Sandra van Wetering

Dr. Sandra van Wetering, COO

Sandra van Wetering is responsible for the day to day management of all operational activities related to the company’s technology, and as such is responsible for the proper execution of product development, manufacturing, regulatory and clinical activities, from proof of principle to approved DCOne®-based therapeutic products (US/EU). Sandra holds a PhD in immunology and worked for more than 10 years in academia where she obtained broad knowledge of immunological techniques, cell culture and tissue engineering.
Before joining DCPrime in 2007, she worked for 3 years as a scientist at Pharming N.V. where she headed the bio-immunological group and was responsible for both non-clinical and clinical assay development. Furthermore, she was closely involved in new target identification, and a member of the project group responsible for filing products for EMA/FDA approval.



Last updated: september 1, 2016